TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: COR-PRIM: Problem-based Learning in Patient Education After an Event of Coronary Heart Disease. A Randomised Study in Primary Care of Long-term Effects on Self-care
Brief Summary: The hypothesis is that problem based learning (PBL) in patient education positively affects self-care agency of lifestyle changes after an event of coronary heart disease (CHD). The investigators therefore aim to determine whether long-term follow-up in primary health care in patient education involving PBL affects self-care behaviour in terms of patients' beliefs, self-efficacy and empowerment to make lifestyle changes. The general aim is to evaluate if PBL in patient education after CHD affects long-term self-care in relation to present lifestyle goals. Another aim of the study is to perform an economic assessment of long term effects of life style changes reached by using PBL after en event of CHD.


Options:
A: Arm Label: PBL- patient education; Type: EXPERIMENTAL; Interventions: Behavioral: PBL in patient education, Behavioral: Mailed patient information | Arm Label: Mailed patient information; Type: EXPERIMENTAL; Interventions: Behavioral: Mailed patient information | Intervention Type: BEHAVIORAL; Name: PBL in patient education; Assigned to Arm(s): PBL- patient education | Intervention Type: BEHAVIORAL; Name: Mailed patient information; Assigned to Arm(s): Mailed patient information, PBL- patient education
B: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Prehab Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Prehab Intervention | Intervention Type: BEHAVIORAL; Name: Prehab Intervention; Assigned to Arm(s): Prehab Intervention
C: Arm Label: Attention Control Group (AC); Type: ACTIVE_COMPARATOR; Interventions: Other: Mediterranean Diet Recommendations, Other: Physical Activity Recommendations | Arm Label: HV-HIIT; Type: EXPERIMENTAL; Interventions: Other: HIGH VOLUME (HV) Supervised exercise, Other: Mediterranean Diet Recommendations | Arm Label: LV-HIIT; Type: EXPERIMENTAL; Interventions: Other: Mediterranean Diet Recommendations, Other: LOW VOLUME (LW) Supervised exercise | Intervention Type: OTHER; Name: HIGH VOLUME (HV) Supervised exercise; Assigned to Arm(s): HV-HIIT | Intervention Type: OTHER; Name: Mediterranean Diet Recommendations; Assigned to Arm(s): Attention Control Group (AC), HV-HIIT, LV-HIIT | Intervention Type: OTHER; Name: Physical Activity Recommendations; Assigned to Arm(s): Attention Control Group (AC) | Intervention Type: OTHER; Name: LOW VOLUME (LW) Supervised exercise; Assigned to Arm(s): LV-HIIT
D: Arm Label: Maintenance program; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Control | Intervention Type: BEHAVIORAL; Name: Exercise training; Assigned to Arm(s): Maintenance program | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: COR-PRIM: Problem-based Learning in Patient Education After an Event of Coronary Heart Disease. A Randomised Study in Primary Care of Long-term Effects on Self-care
Brief Summary: The hypothesis is that problem based learning (PBL) in patient education positively affects self-care agency of lifestyle changes after an event of coronary heart disease (CHD). The investigators therefore aim to determine whether long-term follow-up in primary health care in patient education involving PBL affects self-care behaviour in terms of patients' beliefs, self-efficacy and empowerment to make lifestyle changes. The general aim is to evaluate if PBL in patient education after CHD affects long-term self-care in relation to present lifestyle goals. Another aim of the study is to perform an economic assessment of long term effects of life style changes reached by using PBL after en event of CHD.


Options:
A: Arm Label: PBL- patient education; Type: EXPERIMENTAL; Interventions: Behavioral: PBL in patient education, Behavioral: Mailed patient information | Arm Label: Mailed patient information; Type: EXPERIMENTAL; Interventions: Behavioral: Mailed patient information | Intervention Type: BEHAVIORAL; Name: PBL in patient education; Assigned to Arm(s): PBL- patient education | Intervention Type: BEHAVIORAL; Name: Mailed patient information; Assigned to Arm(s): Mailed patient information, PBL- patient education
B: Arm Label: usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Arm Label: educational program+telephone follow up; Type: EXPERIMENTAL; Interventions: Behavioral: educational program+telephone follow up | Intervention Type: BEHAVIORAL; Name: educational program+telephone follow up; Assigned to Arm(s): educational program+telephone follow up | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): usual care
C: Arm Label: Explanation on cardiac rehabilitation; Type: EXPERIMENTAL; Interventions: Behavioral: Increasing awareness to cardiac rehabilitation programs | Arm Label: Usual care with no intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Increasing awareness to cardiac rehabilitation programs; Assigned to Arm(s): Explanation on cardiac rehabilitation
D: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational Reminder | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Educational Reminder | Intervention Type: BEHAVIORAL; Name: Educational Reminder; Assigned to Arm(s): Control, Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective Randomised Phase III Trial to Evaluate Optimal Treatment Duration of First-line Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Primary Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
Brief Summary: The purpose of this study is to determine whether the early and continuous addition of bevacizumab for up to 30 months to the standard chemotherapy is more effective than the early and continuous addition of bevacizumab for up to 15 months.


Options:
A: Arm Label: Farletuzumab; Type: EXPERIMENTAL; Interventions: Drug: Farletuzumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Farletuzumab; Assigned to Arm(s): Farletuzumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Olaparib tablets p.o. 300mg twice daily; Type: EXPERIMENTAL; Interventions: Drug: Olaparib 300mg tablets | Arm Label: Placebo tablets p.o. twice daily; Type: PLACEBO_COMPARATOR; Interventions: Drug: Olaparib 300mg tablets | Intervention Type: DRUG; Name: Olaparib 300mg tablets; Assigned to Arm(s): Olaparib tablets p.o. 300mg twice daily, Placebo tablets p.o. twice daily
C: Arm Label: Ovarian cancer; Type: EXPERIMENTAL; Interventions: Drug: Oral rucaparib | Intervention Type: DRUG; Name: Oral rucaparib; Assigned to Arm(s): Ovarian cancer
D: Arm Label: Control Arm; Type: OTHER; Interventions: Biological: Bevacizumab, Drug: Paclitaxel, Drug: Carboplatin, Other: specialized pathology review (Germany only) | Arm Label: Research Arm; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Other: specialized pathology review (Germany only) | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Control Arm | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Control Arm, Research Arm | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Control Arm, Research Arm | Intervention Type: OTHER; Name: specialized pathology review (Germany only); Assigned to Arm(s): Control Arm, Research Arm

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-dose Combinations Compared With Individual Components and Placebo When Administered to Patients With Stable Chronic Obstructive Pulmonary Disease.
Brief Summary: The objective is to provide data supporting the use of LAS40464 as an efficacious and safe maintenance bronchodilator treatment of patients with Chronic Obstructive Pulmonary Disease (COPD).


Options:
A: Arm Label: Aclidinium/Formoterol 400/6 μg; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide/Formoterol Fumarate | Arm Label: Aclidinium/Formoterol 400/12 μg; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide/Formoterol Fumarate | Arm Label: Aclidinium monotherapy 400 μg; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide | Arm Label: Formoterol monotherapy 12 μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol Fumarate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium Bromide/Formoterol Fumarate; Assigned to Arm(s): Aclidinium/Formoterol 400/6 μg | Intervention Type: DRUG; Name: Aclidinium Bromide/Formoterol Fumarate; Assigned to Arm(s): Aclidinium/Formoterol 400/12 μg | Intervention Type: DRUG; Name: Aclidinium Bromide; Assigned to Arm(s): Aclidinium monotherapy 400 μg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Formoterol Fumarate; Assigned to Arm(s): Formoterol monotherapy 12 μg
B: Arm Label: COPD subjects; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Non-smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Intervention Type: OTHER; Name: Novel endpoint determination; Assigned to Arm(s): COPD subjects, Non-smoker controls, Smoker controls
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide/Formoterol Fumarate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol Fumarate | Intervention Type: DRUG; Name: Aclidinium Bromide/Formoterol Fumarate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Formoterol Fumarate; Assigned to Arm(s): 2
D: Arm Label: Aclidinium Bromide / Formoterol Fumarate; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide / Formoterol Fumarate | Arm Label: Salmeterol / Fluticasone propionate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol / Fluticasone | Intervention Type: DRUG; Name: Aclidinium Bromide / Formoterol Fumarate; Assigned to Arm(s): Aclidinium Bromide / Formoterol Fumarate | Intervention Type: DRUG; Name: Salmeterol / Fluticasone; Assigned to Arm(s): Salmeterol / Fluticasone propionate

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-dose Combinations Compared With Individual Components and Placebo When Administered to Patients With Stable Chronic Obstructive Pulmonary Disease.
Brief Summary: The objective is to provide data supporting the use of LAS40464 as an efficacious and safe maintenance bronchodilator treatment of patients with Chronic Obstructive Pulmonary Disease (COPD).


Options:
A: Arm Label: Aclidinium 200 μg once-daily; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): Aclidinium 200 μg once-daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Aclidinium 400 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide 400 μg bid | Arm Label: Tiotropium 18 μg once-daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium 18 μg once-daily | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide 400 μg bid; Assigned to Arm(s): Aclidinium 400 μg bid | Intervention Type: DRUG; Name: Tiotropium 18 μg once-daily; Assigned to Arm(s): Tiotropium 18 μg once-daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Aclidinium/Formoterol 400/6 μg; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide/Formoterol Fumarate | Arm Label: Aclidinium/Formoterol 400/12 μg; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide/Formoterol Fumarate | Arm Label: Aclidinium monotherapy 400 μg; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide | Arm Label: Formoterol monotherapy 12 μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol Fumarate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium Bromide/Formoterol Fumarate; Assigned to Arm(s): Aclidinium/Formoterol 400/6 μg | Intervention Type: DRUG; Name: Aclidinium Bromide/Formoterol Fumarate; Assigned to Arm(s): Aclidinium/Formoterol 400/12 μg | Intervention Type: DRUG; Name: Aclidinium Bromide; Assigned to Arm(s): Aclidinium monotherapy 400 μg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Formoterol Fumarate; Assigned to Arm(s): Formoterol monotherapy 12 μg
D: Arm Label: Aclidinium bromide 200 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide 200 μg bid | Arm Label: Aclidininum bromide 400 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide 400 μg bid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide 200 μg bid; Assigned to Arm(s): Aclidinium bromide 200 μg bid | Intervention Type: DRUG; Name: Aclidinium bromide 400 μg bid; Assigned to Arm(s): Aclidininum bromide 400 μg bid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of a Programme of Exercise on Physical Function in Survivors of Critical Illness Following Discharge From the Intensive Care Unit (ICU): a Randomised Controlled Trial
Brief Summary: The purpose of this study is to test if a 6-week programme of exercise improves physical function and health related quality of life in patients following intensive care who are discharged from hospital. In this study the investigators will compare the physical function and health related quality of life of patients who attend the programme with patients who do not. The 6 week exercise programme will be run by physiotherapy staff, and will mostly take place in a hospital gym. The investigators will measure patients' physical function, exercise capacity, level of breathlessness and their quality of life before and after the 6-week programme, and 6 months later. The investigators will also interview patients to ask their views about the acceptability, enjoyment and satisfaction with the exercise programme. If this study shows that the physical function and health related quality of life are improved in those who took part in the exercise programme, then it will provide useful information which will help the development of services for patients after critical illness. The results will also provide information which will help us design future clinical trials for this patient population.


Options:
A: N/A
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Pulmonary Rehabilitation | Intervention Type: OTHER; Name: Pulmonary Rehabilitation; Assigned to Arm(s): Intervention
C: Arm Label: Exercise programme; Type: EXPERIMENTAL; Interventions: Other: Exercise Programme | Arm Label: Standard Care; Type: OTHER; Interventions: Other: Standard Care | Intervention Type: OTHER; Name: Exercise Programme; Assigned to Arm(s): Exercise programme | Intervention Type: OTHER; Name: Standard Care; Assigned to Arm(s): Standard Care
D: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre Phase 3 Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21 Compared With Sevelamer Carbonate in Dialysis Patients With Hyperphosphataemia. Extension Study for Protocol PA-CL-05A (NCT01324128)
Brief Summary: This is a Phase 3, randomised, active controlled, multicentre extension study to investigate the long-term safety and efficacy of PA21, a phosphate binder, for control of hyperphosphataemia in dialysis patients. This is an extension study to PA-CL-05A (NCT01324128), subjects have already been enrolled and have been treated with study medication for at least 24 weeks.


Options:
A: Arm Label: 1 g/day; Type: EXPERIMENTAL; Interventions: Drug: ferric citrate | Arm Label: 6 g/day; Type: EXPERIMENTAL; Interventions: Drug: ferric citrate | Arm Label: 8 g/day; Type: EXPERIMENTAL; Interventions: Drug: ferric citrate | Intervention Type: DRUG; Name: ferric citrate; Assigned to Arm(s): 1 g/day, 6 g/day, 8 g/day
B: Arm Label: Sevelamer Carbonate; Type: EXPERIMENTAL; Interventions: Drug: Sevelamer Carbonate | Arm Label: calcium carbonate; Type: ACTIVE_COMPARATOR; Interventions: Drug: calcium carbonate | Intervention Type: DRUG; Name: Sevelamer Carbonate; Assigned to Arm(s): Sevelamer Carbonate | Intervention Type: DRUG; Name: calcium carbonate; Assigned to Arm(s): calcium carbonate
C: Arm Label: Sevelamer; Type: EXPERIMENTAL; Interventions: Drug: Sevelamer | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sevelamer; Assigned to Arm(s): Sevelamer | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: PA21; Type: EXPERIMENTAL; Interventions: Drug: PA21 (2.5 g tablet containing 500 mg iron) | Arm Label: Sevelamer carbonate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sevelamer carbonate | Intervention Type: DRUG; Name: PA21 (2.5 g tablet containing 500 mg iron); Assigned to Arm(s): PA21 | Intervention Type: DRUG; Name: Sevelamer carbonate; Assigned to Arm(s): Sevelamer carbonate

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Transepithelial Corneal Collagen Crosslinking for Keratoconus and Corneal Ectasia
Brief Summary: Corneal collagen crosslinking (CXL) has been proposed as an effective method of reducing progression of both keratoconus and corneal ectasia after surgery, as well as possibly decreasing the steepness of the cornea in these pathologies. During previous studies of the CXL procedure, the surface epithelial cells have been removed. Transepithelial crosslinking in which the epithelium is not removed has been proposed to offer a number of advantages over traditional crosslinking including an increased safety profile by reducing the risk for infection as no epithelial barrier will be broken, faster visual recovery and improved patient comfort in the early postoperative healing period.


Options:
A: Arm Label: 30 minute light duration; Type: ACTIVE_COMPARATOR; Interventions: Drug: riboflavin, Device: UVX Light | Arm Label: 45 minute light duration; Type: ACTIVE_COMPARATOR; Interventions: Device: UVX Light | Intervention Type: DRUG; Name: riboflavin; Assigned to Arm(s): 30 minute light duration | Intervention Type: DEVICE; Name: UVX Light; Assigned to Arm(s): 30 minute light duration, 45 minute light duration
B: Arm Label: Riboflavin drops every minute; Type: ACTIVE_COMPARATOR; Interventions: Drug: Riboflavin | Arm Label: Riboflavin drops every 2 minutes; Type: ACTIVE_COMPARATOR; Interventions: Drug: Riboflavin | Intervention Type: DRUG; Name: Riboflavin; Assigned to Arm(s): Riboflavin drops every 2 minutes | Intervention Type: DRUG; Name: Riboflavin; Assigned to Arm(s): Riboflavin drops every minute
C: Arm Label: Collagen cross-linking; Type: EXPERIMENTAL; Interventions: Procedure: Collagen cross-linking | Arm Label: standard treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Collagen cross-linking; Assigned to Arm(s): Collagen cross-linking
D: Arm Label: antibiotic treatment alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: antibiotic treatment | Arm Label: Crosslinking + Antibiotic; Type: EXPERIMENTAL; Interventions: Device: Crosslinking, Drug: antibiotic treatment | Intervention Type: DEVICE; Name: Crosslinking; Assigned to Arm(s): Crosslinking + Antibiotic | Intervention Type: DRUG; Name: antibiotic treatment; Assigned to Arm(s): Crosslinking + Antibiotic, antibiotic treatment alone

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Stress Reduction for PCOS and Non-PCOS Women
Brief Summary: The purpose of this study is to determine the effects of stress reduction on glucose, blood pressure, quality of life and overall health and well-being in overweight or obese women, either with Polycystic Ovary Syndrome (PCOS) or without PCOS (non-PCOS). Stress reduction treatment sessions will include one or more of the following activities: breathing exercises, meditation, stretching exercises or health education activities.


Options:
A: Arm Label: Distress management; Type: EXPERIMENTAL; Interventions: Behavioral: A cognitive behavior therapy distress management program targeting wellbeing in patients with atrial fibrillation and their relatives | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: A cognitive behavior therapy distress management program targeting wellbeing in patients with atrial fibrillation and their relatives; Assigned to Arm(s): Distress management
B: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Behavioral: Meditation | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Behavioral: Meditation | Arm Label: Group 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Meditation; Assigned to Arm(s): Group 1, Group 2
C: Arm Label: Stress reduction; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Stress reduction | Arm Label: Stress reduction with Health education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Stress reduction with Health education | Intervention Type: BEHAVIORAL; Name: Stress reduction; Assigned to Arm(s): Stress reduction | Intervention Type: BEHAVIORAL; Name: Stress reduction with Health education; Assigned to Arm(s): Stress reduction with Health education
D: Arm Label: Enhanced health education program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced health education | Arm Label: Transcendental Meditation program; Type: EXPERIMENTAL; Interventions: Behavioral: Transcendental Meditation program | Intervention Type: BEHAVIORAL; Name: Enhanced health education; Assigned to Arm(s): Enhanced health education program | Intervention Type: BEHAVIORAL; Name: Transcendental Meditation program; Assigned to Arm(s): Transcendental Meditation program

Answer: C